当前位置：
X-MOL 学术
›
N. Engl. J. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis in Vietnam.
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2024-12-19 , DOI: 10.1056/nejmoa2314325 Greg J Fox,Nguyen Viet Nhung,Nguyen Cam Binh,Nguyen Binh Hoa,Frances L Garden,Andrea Benedetti,Pham Ngoc Yen,Nguyen Kim Cuong,Emily L MacLean,H Manisha Yapa,David W Dowdy,Nguyen Huu Lan,Elyse Guevara-Rattray,Pham Duc Cuong,Ori Solomon,Marcel A Behr,Ben J Marais,Steven M Graham,Dick Menzies,Nguyen Thu Anh,Guy B Marks
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2024-12-19 , DOI: 10.1056/nejmoa2314325 Greg J Fox,Nguyen Viet Nhung,Nguyen Cam Binh,Nguyen Binh Hoa,Frances L Garden,Andrea Benedetti,Pham Ngoc Yen,Nguyen Kim Cuong,Emily L MacLean,H Manisha Yapa,David W Dowdy,Nguyen Huu Lan,Elyse Guevara-Rattray,Pham Duc Cuong,Ori Solomon,Marcel A Behr,Ben J Marais,Steven M Graham,Dick Menzies,Nguyen Thu Anh,Guy B Marks
BACKGROUND
Prevention of drug-resistant tuberculosis is a global health priority. However, trials evaluating the effectiveness of treating Mycobacterium tuberculosis infection among contacts of persons with drug-resistant tuberculosis are lacking.
METHODS
We conducted a double-blind, randomized, controlled trial comparing 6 months of daily levofloxacin (weight-based doses) with placebo to treat M. tuberculosis infection. The trial population comprised household contacts of persons with bacteriologically confirmed rifampicin-resistant or multidrug-resistant (MDR) tuberculosis in Vietnam. Contacts of any age with a positive tuberculin skin test or immunologic impairment were eligible. The primary end point was bacteriologically confirmed tuberculosis within 30 months. Secondary end points included grade 3 or 4 adverse events, death from any cause, and acquired drug resistance.
RESULTS
Of 3948 persons screened for eligibility, 61 (1.5%) had coprevalent tuberculosis (defined as active tuberculosis disease diagnosed before randomization) and 2041 underwent randomization. Of these 2041 participants, 1995 (97.7%) completed 30 months of follow-up, had a primary end-point event, or died. Confirmed tuberculosis occurred in 6 participants (0.6%) in the levofloxacin group and 11 (1.1%) in the placebo group (incidence rate ratio, 0.55; 95% confidence interval [CI], 0.19 to 1.62); this difference was not significant. There was little difference in grade 3 or 4 adverse events between the two groups (risk difference, 1.0 percentage point; 95% CI, -0.3 to 2.4). Adverse events of any grade were reported in 306 participants (31.9%) taking levofloxacin and 125 (13.0%) taking placebo (risk difference, 18.9 percentage points; 95% CI, 14.2 to 23.6). No acquired fluoroquinolone resistance was observed.
CONCLUSIONS
Although the incidence of tuberculosis was lower in the levofloxacin group than in the placebo group at 30 months, the difference was not significant. (Funded by the National Health and Medical Research Council of Australia; VQUIN MDR Australia New Zealand Clinical Trials Registry number, ACTRN12616000215426.).
更新日期：2024-12-19
京公网安备 11010802027423号